Utomilumab
- Generic Name
- Utomilumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1417318-27-4
- Unique Ingredient Identifier
- 6YY8O697VF
- Background
Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT05059522
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸MSK Monmouth, Middletown, New Jersey, United States
RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03636503
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Adrienne G. Waks
- Target Recruit Count
- 100
- Registration Number
- NCT03414658
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- George W. Sledge Jr.
- Target Recruit Count
- 18
- Registration Number
- NCT03364348
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03318900
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients with Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT03290937
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03258008
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmCastration-Resistant Prostate CarcinomaMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Prostate CarcinomaProstate Carcinoma Metastatic in the BoneRefractory Malignant Solid NeoplasmStage IV Prostate Cancer AJCC V8Stage IVA Prostate Cancer AJCC V8Stage IVB Prostate Cancer AJCC V8
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 173
- Registration Number
- NCT03217747
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 409
- Registration Number
- NCT02554812
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇦🇺The Mater Hospital, North Sydney, New South Wales, Australia
🇺🇸Mount Sinai Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT02444793
- Locations
- 🇺🇸
Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.